GlassScriptPhysician profile
Christy Riddle
NPI 1790918951
$5,162.45
in general payments reported to CMS, 2019-2025
24 companies · $2,130 in 2025
The $2,130 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.79 · 2022: $788 · 2023: $549 · 2024: $1,602 · 2025: $2,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,206 · Education: $74.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,205.63 |
| Education | $74.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $833.57 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $828.89 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $509.74 | 2022-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $452.53 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Indivior INC. | $263.86 | 2022-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $257.33 | 2021-2025 | Spravato, Invega Trinza, Invega |
| Neurocrine Biosciences, INC. | $250.29 | 2022-2025 | Ingrezza |
| Corium, LLC | $246.53 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $205.66 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $194.90 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.28 | 2023-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $159.21 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $149.92 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $131.03 | 2021-2023 | Trintellix |
| Lundbeck LLC | $130.60 | 2022-2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $73.41 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $72.84 | 2025 | Cobenfy |
| Tris Pharma INC | $53.73 | 2024-2025 | Dyanavel Xr |
| Braeburn INC. | $41.04 | 2023-2024 | Brixadi |
| Avanir Pharmaceuticals, INC. | $37.66 | 2022 | |
| Sunovion Pharmaceuticals INC. | $32.59 | 2021 | |
| Biogen, INC. | $26.56 | 2025 | Zurzuvae |
| Ultragenyx Pharmaceutical INC. | $18.56 | 2024 | Crysvita |
| Vertical Pharmaceuticals, LLC | $13.72 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Riddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.